Clinical Trials Directory

Trials / Conditions / Metastatic Cervical Cancer

Metastatic Cervical Cancer

19 registered clinical trials studyying Metastatic Cervical Cancer — 6 currently recruiting.

StatusTrialSponsorPhase
RecruitingA Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy
NCT07418749
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3
Not Yet RecruitingQL706 + Chemo ± Bevacizumab in Anti-PD-(L)1-Resistant R/M Cervical Cancer
NCT07186868
Cancer Institute and Hospital, Chinese Academy of Medical Sciences—
RecruitingPD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With
NCT07472153
N.N. Alexandrov National Cancer CentrePhase 2 / Phase 3
RecruitingPRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cerv
NCT06157151
Precigen, IncPhase 2
RecruitingStudy on Disease Characteristics and Treatment in Locally Advanced or Recurrent / Metastatic Cervical Cancer i
NCT06771193
MSD Italia S.r.l.—
Active Not RecruitingDostarlimab and Cobolimab in Advanced Cervical Cancer
NCT06238635
Meghan SheaPhase 2
WithdrawnTislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Ch
NCT05614453
Australia New Zealand Gynaecological Oncology GroupPhase 2
RecruitingPembrolizumab and Lenvatinib in Advanced Cervical Cancer
NCT04865887
Georgetown UniversityPhase 2
UnknownQL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervi
NCT05446883
Qilu Pharmaceutical Co., Ltd.Phase 3
CompletedSafety of Effivia®, a Bevacizumab Biosimilar
NCT06313268
Laboratorios Liomont—
WithdrawnBalstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
NCT04943627
Agenus Inc.Phase 3
CompletedA Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer
NCT04380805
AkesoPhase 2
TerminatedCabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer
NCT04230954
University of South AlabamaPhase 2
TerminatedHER-Seq: A Blood-based Screening Study to Identify Patients With HER2 Mutations for Enrollment Into Clinical R
NCT03786107
Puma Biotechnology, Inc.—
CompletedSHR-1210 in Combination With Apatinib in Patients With Metastatic, Persistent, or Recurrent Cervical Cancer
NCT03816553
Sun Yat-sen UniversityPhase 2
Active Not RecruitingSelf-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
NCT04266886
M.D. Anderson Cancer CenterN/A
TerminatedDurvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
NCT03277482
Dana-Farber Cancer InstitutePhase 1
UnknownHydralazine Valproate for Cervical Cancer
NCT00532818
National Institute of CancerologíaPhase 3
CompletedPazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical
NCT00430781
GlaxoSmithKlinePhase 2